Zebrafish Renal Cell Carcinoma (RCC) Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Renal cell carcinoma (RCC) is the most common form of kidney cancer, accounting for approximately 90% of renal malignancies. Clear cell RCC (ccRCC) is the predominant histological subtype, characterized by distinct molecular features including biallelic VHL inactivation, constitutive HIF-α pathway activation, and downstream upregulation of VEGF, PDGF, and other pro-angiogenic and metabolic targets. Other RCC subtypes include papillary, chromophobe, and collecting duct carcinomas, each with distinct genetic drivers such as MET alterations, TFE3/TFEB translocations, and mTOR pathway mutations. Clinical presentation may include hematuria, flank pain, palpable abdominal mass, and paraneoplastic syndromes, though many cases are now detected incidentally through imaging.

Current treatment for localized RCC includes partial or radical nephrectomy and ablative techniques. Advanced or metastatic RCC is managed with targeted therapies, including VEGF receptor tyrosine kinase inhibitors, mTOR inhibitors, and immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4. Despite these advances, primary and acquired resistance to targeted agents, intratumoral heterogeneity, and the lack of predictive biomarkers for treatment selection remain significant clinical challenges. Zebrafish RCC models provide a rapid in vivo platform for evaluating tumor growth, angiogenesis, HIF pathway activity, anti-angiogenic drug response, and genetic mechanisms of RCC pathogenesis.

Why Zebrafish?

Real-time Vascular Imaging: Transparent larvae enable real-time imaging of tumor angiogenesis and vascular response.
Conserved VHL/HIF Pathway: Conserved VHL/HIF pathway supports mechanistic studies of ccRCC biology.
Rapid Efficacy Testing: Small size allows rapid efficacy testing of anti-angiogenic and mTOR-targeted agents.
Genetic Models: Genetic models enable in vivo dissection of RCC tumor suppressor pathways.

Available Zebrafish Disease Models

We provide RCC models ranging from cell line xenografts to VHL-deficient genetic models and patient-derived xenografts:

Model Name	Induction Method	Features
RCC Cell Line Xenograft Model	Fluorescently labeled human RCC cell lines, such as 786-O, ACHN, Caki-1, 769-P, or A-498, are transplanted into zebrafish embryos or larvae.	A practical model for assessing tumor cell proliferation, survival, migration, and drug response. Suitable for rapid efficacy screening of VEGFR-TKIs, mTOR inhibitors, and combination therapies.
RCC Angiogenesis Xenograft Model	RCC cells are implanted into vascular reporter zebrafish lines, such as Tg(fli1:EGFP) or Tg(kdrl:EGFP), followed by live imaging of tumor-associated vascular response.	Enables quantification of tumor-induced angiogenesis, vessel remodeling, and anti-angiogenic drug activity. Highly relevant for testing VEGF/VEGFR pathway inhibitors, given the vascular nature of ccRCC.
VHL-Deficient Zebrafish Genetic Model	VHL gene function is disrupted in zebrafish, through morpholino knockdown or transgenic approaches, to model VHL loss-driven phenotypes.	Recapitulates early features of ccRCC, including HIF-α pathway activation, increased angiogenesis, and renal epithelial abnormalities. Useful for studying VHL/HIF axis biology, HIF2α inhibitor evaluation, and disease mechanism dissection.
Patient-Derived RCC Xenograft Model	Fresh tumor cells from patient RCC surgical specimens or biopsy samples are fluorescently labeled and implanted into zebrafish larvae.	Provides a patient-relevant platform for evaluating heterogeneous tumor behavior and drug sensitivity. Supports translational research and personalized treatment response assessment.

Phenotypic Evaluation

Drug Response and Safety

Reduction in tumor burden
Inhibition of angiogenesis or migration
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Tumor Growth

Tumor fluorescence area or intensity
Tumor cell expansion over time
Tumor growth inhibition after treatment

Angiogenesis

Tumor-induced vessel sprouting and density
Vessel remodeling around tumor
Inhibition of vascular response after treatment

Migration and Invasion

Migration distance from implantation site
Number of disseminated tumor foci
Tumor cell invasion pattern

Key Applications

In Vivo Drug Screening: In vivo RCC drug screening for VEGFR-TKIs, mTOR inhibitors, HIF2α inhibitors, and immunotherapy combinations.
Anti-angiogenic Evaluation: Anti-angiogenic therapy evaluation using vascular reporter zebrafish lines, leveraging the highly vascular nature of ccRCC.
VHL/HIF Studies: VHL/HIF pathway mechanistic studies using genetic zebrafish models of VHL deficiency.
Migration and Invasion: Tumor migration and invasion assessment using live fluorescence imaging of labeled RCC cells.
Patient-Derived Profiling: Patient-derived tumor response profiling to support translational and personalized oncology research.

Study Examples

This study characterized the renal epithelial abnormalities in vhl-deficient zebrafish larvae as a model of early ccRCC. The vhl−/− zebrafish kidney displayed features consistent with ccRCC initiation, including increased cell proliferation, abnormal cilia, and activated HIF target gene expression.

Fig. 1. VHL loss in zebrafish pronephros induces renal epithelial abnormalities and activated HIF pathway signaling (Noonan HR, Metelo AM, et al., 2016).

This study investigated the relationship between PTEN loss and sensitivity to mTOR inhibitors in ccRCC, using zebrafish xenografts as one of the in vivo platforms. PTEN-deficient ccRCC cells were more sensitive to temsirolimus-mediated inhibition of cell migration in zebrafish xenografts and tumor growth in mouse models.

Fig. 2. PTEN-deficient ccRCC cells show increased sensitivity to temsirolimus in zebrafish xenografts (Liu XL, Zhang GM, et al. 2022).

Accelerate Ovarian Cancer Research with Zebrafish Models

Advance renal cell carcinoma research with zebrafish models for in vivo tumor growth analysis, angiogenesis assessment, VHL/HIF pathway studies, and anti-angiogenic and mTOR-targeted drug evaluation.

Contact Our Scientists

References

Noonan HR, Metelo AM, et al. Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. Disease Models & Mechanisms 9(8), 873–884 (2016).
Liu XL, Zhang GM, et al. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. Acta Pharmacologica Sinica 43(9), 2397–2409 (2022).

For research use only. Not intended for any clinical use.